Stay updated on Viatris Press Releases

Sign up to get notified when there's something new on the Viatris Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Viatris Press Releases page

  1. Check
    4 days ago
    Change Detected
    Summary
    Viatris has published Phase 2b CARE Study data for Cenerimod in Lancet Rheumatology, while the announcement for their third quarter financial results has been removed.
    Difference
    20%
    Check dated 2024-12-22T06:31:07.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    Viatris has added several significant press releases, including their third quarter financial results for 2024 and a licensing agreement with Lexicon Pharmaceuticals, while also removing various policy and compliance documents from their website.
    Difference
    100%
    Check dated 2024-11-23T05:19:38.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Viatris has made several significant announcements, including being named to Forbes' World's Top Companies for Women 2024 and reporting positive results from a Phase 3 study of EFFEXOR® for anxiety in Japan.
    Difference
    100%
    Check dated 2024-11-08T18:57:53.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Viatris has been recognized in Forbes' World's Top Companies for Women 2024 list and will participate in upcoming healthcare conferences, while previous announcements regarding cash tender offers and a presentation on Cenerimod have been removed.
    Difference
    100%
    Check dated 2024-11-01T11:34:14.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    Viatris has announced an exclusive licensing agreement with Lexicon Pharmaceuticals for Sotagliflozin in all markets outside of the U.S. and Europe, while the report on their second quarter financial results for 2024 has been removed.
    Difference
    100%
    Check dated 2024-10-17T19:57:13.000Z thumbnail image
  9. Check
    77 days ago
    Change Detected
    Summary
    Viatris has announced positive results from a Phase 3 study of EFFEXOR® for anxiety in Japanese adults and has been recognized by Forbes as one of the world's best employers for the fourth consecutive year.
    Difference
    100%
    Check dated 2024-10-10T14:35:34.000Z thumbnail image

Stay in the know with updates to Viatris Press Releases

Enter your email address, and we'll notify you when there's something new on the Viatris Press Releases page.